Michael LÃ¼bbert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7748743/publications.pdf

Version: 2024-02-01

117 papers	9,524 citations	66343 42 h-index	38395 95 g-index
123 all docs	123 docs citations	123 times ranked	11717 citing authors

#	Article	IF	Citations
1	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. New England Journal of Medicine, 2013, 369, 111-121.	27.0	1,284
2	New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood, 2007, 110, 4385-4395.	1.4	719
3	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood, 2012, 119, 2114-2121.	1.4	553
4	Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology, 2011, 29, 1987-1996.	1.6	514
5	Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2â€²-deoxycytidine (decitabine) treatment. Blood, 2002, 100, 2957-2964.	1.4	511
6	Acute myeloid leukemia: Epidemiology and etiology. Cancer, 2006, 107, 2099-2107.	4.1	500
7	Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clinical Epigenetics, 2010, 1, 117-136.	4.1	357
8	Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clinical Epigenetics, 2016, 8, 57.	4.1	333
9	DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nature Genetics, 2017, 49, 1052-1060.	21.4	235
10	Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. British Journal of Haematology, 2001, 114, 349-357.	2.5	228
11	A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica, 2012, 97, 393-401.	3.5	219
12	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	30.7	216
13	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood, 2014, 124, 1426-1433.	1.4	204
14	<scp>ZEB</scp> 1â€associated drug resistance in cancer cells is reversed by the class I <scp>HDAC</scp> inhibitor mocetinostat. EMBO Molecular Medicine, 2015, 7, 831-847.	6.9	191
15	Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica, 2013, 98, 208-216.	3.5	176
16	The DNA demethylating agent 5-aza-2â€²-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leukemia Research, 2010, 34, 899-905.	0.8	164
17	Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood, 2013, 121, 170-177.	1.4	164
18	Clinical development of demethylating agents in hematology. Journal of Clinical Investigation, 2014, 124, 40-46.	8.2	128

#	Article	IF	Citations
19	Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica, 2006, 91, 1513-22.	3.5	117
20	Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes. Clinical Cancer Research, 2009, 15, 3705-3715.	7.0	106
21	Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia, 2021, 35, 1873-1889.	7.2	104
22	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	3.5	93
23	Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. Nature Communications, 2020, 11, 1659.	12.8	92
24	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood, 2021, 137, 3093-3104.	1.4	91
25	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Annals of Hematology, 2016, 95, 191-199.	1.8	84
26	The effects of 5-aza-2â€²-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leukemia Research, 2004, 28, 785-790.	0.8	81
27	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemiaâ€"results of the AMLSG 11-08 trial. Leukemia, 2018, 32, 1621-1630.	7.2	81
28	Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. Leukemia, 2019, 33, 945-956.	7.2	73
29	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood, 2020, 136, 3041-3050.	1.4	73
30	Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Science Translational Medicine, 2020, 12, .	12.4	70
31	Superiority of prolonged low-dose azanucleoside administration?. Cancer, 2006, 106, 1744-1750.	4.1	67
32	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 Ã— 2, Phase II Trial. Journal of Clinical Oncology, 2020, 38, 257-270.	1.6	63
33	Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget, 2016, 7, 12840-12856.	1.8	63
34	Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics, 2016, 11, 858-870.	2.7	60
35	Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood, 2007, 110, 1080-1082.	1.4	59
36	The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer, 2015, 15, 947.	2.6	58

#	Article	IF	Citations
37	Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. British Journal of Haematology, 1998, 103, 72-78.	2.5	56
38	DNA Methylation as a Therapeutic Target in Hematologic Disorders: Recent Results in Older Patients with Myelodysplasia and Acute Myeloid Leukemia. International Journal of Hematology, 2004, 80, 128-135.	1.6	55
39	Clinical Results of Hypomethylating Agents in AML Treatment. Journal of Clinical Medicine, 2015, 4, 1-17.	2.4	49
40	DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60Âyears with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer, 2015, 15, 430.	2.6	47
41	DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML. Current Pharmaceutical Biotechnology, 2006, 7, 315-321.	1.6	46
42	HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leukemia Research, 2012, 36, 1055-1062.	0.8	45
43	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Advances, 2020, 4, 6342-6352.	5.2	45
44	Hematologic and molecular spontaneous remission following sepsis in acute monoblastic leukemia with translocation (9;11): a case report and review of the literature. European Journal of Haematology, 2004, 73, 62-66.	2.2	44
45	DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. Seminars in Cancer Biology, 2018, 51, 68-79.	9.6	42
46	Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leukemia Research, 2007, 31, 497-506.	0.8	39
47	Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. Leukemia Research, 2018, 72, 20-26.	0.8	35
48	Quantitative analyses of DAPK1 methylation in AML and MDS. International Journal of Cancer, 2012, 131, E138-42.	5.1	34
49	Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Genome Medicine, 2014, 6, 34.	8.2	34
50	Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2â€™-deoxycytidine (decitabine). Leukemia Research, 2004, 28, 1267-1271.	0.8	33
51	Williamsâ€“Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO. Oncogene, 2004, 23, 9070-9081.	5.9	32
52	Clinical Results With the DNA Hypomethylating Agent 5-Aza-2â€²-Deoxycytidine (Decitabine) in Patients With Myelodysplastic Syndromes: An Update. Seminars in Hematology, 2012, 49, 330-341.	3.4	32
53	Structure-activity studies on N -Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. European Journal of Medicinal Chemistry, 2018, 144, 52-67.	5.5	30
54	Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica, 2008, 93, 1728-1733.	3.5	27

#	Article	IF	Citations
55	Immune response as a possible mechanism of long-lasting disease control in spontaneous remission of MLL/AF9-positive acute myeloid leukemia. Annals of Hematology, 2012, 91, 27-32.	1.8	26
56	Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica, 2014, 99, 1456-1464.	3.5	26
57	Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leukemia Research, 2013, 37, 190-196.	0.8	23
58	Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat. PLoS ONE, 2013, 8, e75258.	2.5	23
59	Differential regulation of interleukin-6 expression in human fibroblasts by tumor necrosis factor-Î± and lymphotoxin. FEBS Letters, 1990, 270, 152-156.	2.8	22
60	Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy. Journal of Cellular Biochemistry, 2008, 104, 2059-2070.	2.6	22
61	Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). Annals of Hematology, 2015, 94, 2003-2013.	1.8	20
62	Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy. Annals of Hematology, 2017, 96, 559-565.	1.8	20
63	Elevated fetal haemoglobin is a predictor of better outcome inÂ<scp>MDS</scp>/<scp>AML</scp> patients receiving 5â€ºazaâ€²â€²â€²deoxycytidine (Decitabine). British Journal of Haematology, 2017, 176, 609-617.	2.5	20
64	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57.	0.8	20
65	Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges. Cancer, 2015, 121, 498-501.	4.1	18
66	Decitabine Induces Gene Derepression on Monosomic Chromosomes: In Vitro and In Vivo Effects in Adverse-Risk Cytogenetics AML. Cancer Research, 2021, 81, 834-846.	0.9	18
67	AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms. Oncogene, 2021, 40, 5665-5676.	5.9	18
68	Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)). The Cochrane Library, 2018, 2018, CD011960.	2.8	17
69	Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2171-2180.	2.5	16
70	Immunotherapy in adult acute leukemia. Leukemia Research, 2017, 60, 63-73.	0.8	16
71	Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. British Journal of Haematology, 2018, 182, 830-842.	2.5	16
72	Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis. Annals of Hematology, 2021, 100, 2339-2350.	1.8	16

#	Article	IF	Citations
73	Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediatedlysozymerepression. Journal of Leukocyte Biology, 2006, 80, 1462-1472.	3.3	15
74	Can we predict responsiveness to hypomethylating agents in AML?. Seminars in Hematology, 2019, 56, 118-124.	3.4	15
75	Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. Annals of Hematology, 2020, 99, 1551-1560.	1.8	15
76	Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report. Annals of Hematology, 2021, 100, 841-842.	1.8	15
77	Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome. Haematologica, 2019, 104, 59-69.	3.5	14
78	Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients. Clinical Epigenetics, 2021, 13, 77.	4.1	14
79	Interleukin-4 regulates mRNA accumulation of macrophage-colony stimulating factor by fibroblasts: synergism with interleukin-1Î². British Journal of Haematology, 1990, 76, 7-11.	2.5	13
80	Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation. British Journal of Haematology, 2011, 153, 612-622.	2.5	13
81	The epigenetics of breast cancer â€“ Opportunities for diagnostics, risk stratification and therapy. Epigenetics, 2022, 17, 612-624.	2.7	13
82	Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?. Current Opinion in Hematology, 2010, 17, 85-90.	2.5	12
83	Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of inv(16) AML in a CBL mutated clonal hematopoiesis. Leukemia Research, 2016, 47, 41-46.	0.8	12
84	Estimating and comparing adverse event probabilities in the presence of varying followâ€up times and competing events. Pharmaceutical Statistics, 2021, 20, 1125-1146.	1.3	12
85	When Azanucleoside Treatment Can Be Curative: Nonintensive Bridging Strategy Before Allografting in Older Patients With Myelodysplastic Syndrome/Acute Myeloid Leukemia. Journal of Clinical Oncology, 2013, 31, 822-823.	1.6	11
86	Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia. Epigenetics, 2017, 12, 886-896.	2.7	11
87	The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. Leukemia Research, 2014, 38, 340-345.	0.8	10
88	Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. Leukemia Research, 2019, 85, 106192.	0.8	9
89	Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. Genes Chromosomes and Cancer, 2019, 58, 689-697.	2.8	8
90	Netboost: Boosting-Supported Network Analysis Improves High-Dimensional Omics Prediction in Acute Myeloid Leukemia and Huntingtonâ€™s Disease. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2021, 18, 2635-2648.	3.0	8

#	Article	IF	Citations
91	First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience. Cancer Immunology, Immunotherapy, 2022, 71, 2913-2928.	4.2	8
92	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. Annals of Hematology, 2017, 96, 895-904.	1.8	7
93	The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia. Advances in Therapy, 2022, 39, 1474-1488.	2.9	7
94	Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes. Leukemia and Lymphoma, 2017, 58, 2264-2267.	1.3	6
95	Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials. Cancers, 2020, 12, 3334.	3.7	6
96	Treatment of Patients up to 60 Years with High Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. Blood, 2006, 108, 433-433.	1.4	6
97	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. British Journal of Haematology, 2019, 185, 583-587.	2.5	5
98	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica, 2021, 106, 2986-2989.	3.5	5
99	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 609-609.	1.4	5
100	Impact of the Injection Site on Growth Characteristics, Phenotype and Sensitivity towards Cytarabine of Twenty Acute Leukaemia Patient-Derived Xenograft Models. Cancers, 2020, 12, 1349.	3.7	4
101	First-in-Human Study of WT1 Recombinant Protein Vaccination in Elderly Patients with AML in Remission: A Single-Center Experience. Blood, 2021, 138, 1278-1278.	1.4	4
102	Cytogenetic responses in highâ€risk myelodysplastic syndrome following lowâ€dose treatment with the DNA methylation inhibitor 5â€azaâ€2â€²â€deoxycytidine. British Journal of Haematology, 2001, 114, 349-357.	2.5	3
103	The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. Experimental Hematology, 2017, 55, 76-85.e3.	0.4	3
104	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes and Cancer, 2018, 57, 547-556.	2.8	3
105	Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia. Annals of Hematology, 2021, 100, 63-78.	1.8	3
106	Innovative strategies for adverse karyotype acute myeloid leukemia. Current Opinion in Hematology, 2017, 24, 89-98.	2.5	2
107	10-day vs 5-day decitabine: equivalence cannot be concluded. Lancet Haematology,the, 2019, 6, e177.	4.6	2
108	Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine. British Journal of Haematology, 2020, 189, e194-e197.	2.5	1

#	Article	IF	Citations
109	Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. Annals of Hematology, 2021, 100, 1637-1640.	1.8	1
110	The AML-associated K313 mutation enhances C/EBPÎ± activity by leading to C/EBPÎ± overexpression. Cell Death and Disease, 2021, 12, 675.	6.3	1
111	Treatment of Hematologic Malignancies with DNA Hypomethylating Agents. , 2014, , 145-170.		1
112	Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes. Blood Advances, 2022, , .	5.2	1
113	Optimizing epigenetic therapy for myelodysplastic syndromes: issues and strategies. Leukemia Research, 2009, 33, S1.	0.8	0
114	Epigenetic therapy for myelodysplastic syndromes has entered center stage. Leukemia Research, 2009, 33, S27-S28.	0.8	0
115	EORTC Leukemia Group achievements. European Journal of Cancer, Supplement, 2012, 10, 94-98.	2.2	0
116	Epigenetic Modifications Mediated by the AML1/ETO and MLL Leukemia Fusion Proteins. , 2014, , 121-144.		0
117	Prospective Randomized Comparison of High Dose AraC and AutoPBSCT as Late Consolidation for Patients â‰60 Years with Standard Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. Blood, 2006, 108, 607-607.	1.4	0